Latest Europe News

Nufarm’s 2025 AGM revealed a resilient FY24 performance despite industry headwinds, with strategic investments in omega-3 canola, biofuels, and cost-saving initiatives setting the stage for growth in FY25.

Redivium Limited has successfully completed the formalities for listing a €25 million green bond, aimed at accelerating its sustainable battery recycling projects across Europe, including the UK, Czech Republic, and Romania.

Redivium Limited’s recent entitlement offer failed to meet the minimum subscription, leading to its cancellation and full refunds to investors. The company now pivots towards a green bond funding strategy to support its battery recycling ambitions.

ResMed Inc. reported robust financial results for the quarter ended December 31, 2024, with a 10% increase in net revenue and a 65% jump in net income, driven by strong demand across its Sleep and Breathing Health and Residential Care Software segments.

European Metals Holdings has made significant strides in developing its Cinovec Lithium Project, announcing a strategic relocation of its processing plant and ongoing enhancements to production capacity and cost efficiency. The Definitive Feasibility Study is on track for mid-2025 completion, promising a clearer outlook on the project's economic potential.

European Metals Holdings Limited has clarified its recent Concept Study results for the Cinovec lithium project, retracting previous production targets while highlighting a potential increase in production capacity pending Definitive Feasibility Study confirmation.

Cardiex has kicked off deliveries of its CONNEQT Pulse arterial health monitors in the U.S., reporting strong preorder momentum and a 150% sales increase in December. The company’s strategic operational shifts and pharma partnerships set the stage for sustained growth in 2025.

Nagambie Resources has updated its JORC Inferred Resource at the Nagambie Mine, reflecting higher gold and antimony prices and ongoing drilling efforts to expand and upgrade the deposit.

Althea Group Holdings has obtained Federal Court orders confirming the validity of past share sales despite previous failures to lodge required Cleansing Notices, paving the way for the reinstatement of its shares to trading.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.

Alexium International Group reports a 16% sales increase in Q2 FY25 despite ongoing mattress market softness, driven by strategic product diversification and supply chain improvements.